<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2018.86085</article-id><article-id pub-id-type="publisher-id">ACM-26241</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20180600000_13933561.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  胞壁酰二肽对儿童急性白血病骨髓树突状细胞功能的影响
  Effect of Muramyl Dipeptide on the Immunifaction of Dendritic Cells Derived from Bone Marrow in Children with Acute Leukemia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晓玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>政</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>立荣</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>临沂市人民医院儿内三科，山东 临沂</addr-line></aff><aff id="aff3"><addr-line>上海中医药大学康复医学院，上海</addr-line></aff><aff id="aff4"><addr-line>青岛大学医学院附属医院小儿血液科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>31</day><month>07</month><year>2018</year></pub-date><volume>08</volume><issue>06</issue><fpage>507</fpage><lpage>513</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨胞壁酰二肽(MDP)对儿童急性白血病骨髓树突状细胞(DC)功能的影响。方法：应用Ficoll-Hypaque法分离急性白血病患儿骨髓单个核细胞，对照组：用细胞因子诱导培养DC；实验组实验组分为5个亚组，1组：与对照组等量的MNC+ MDP (10 ug/l)，2~5组分别对应为：与对照组等量的MNC + 与对照组等量的细胞因子 + 不同浓度的MDP (10
   <sup>2</sup> ug/l，10
   <sup>2</sup> ug/l，10
   <sup>3</sup> ug/l，10
   <sup>4</sup> ug/l)；分别诱导培养DC，第9天收获各组DC，与同种异体外周血T淋巴细胞混合反应96 h，观察淋巴细胞的增殖情况，ELISA方法检测上清液中IL-12、IFN-γ的含量；经HL-60抗原致敏后的DC与T淋巴细胞混合培养6 d后，加入HL-60细胞共同孵育12 h，LDH释放改良法检测各组细胞毒T淋巴细胞(CTL)的杀伤活性。结果：1) 混合淋巴细胞反应显示：① T细胞扩增指数：固定刺激细胞数，不同组比较，对照组与1组、2组比较均无显著性差异(p均 &gt; 0.05)；3组、4组、5组T细胞扩增指数明显高于对照组，亦明显高于1组(p均 &lt; 0.01)。当刺激细胞数量为1 &#215; 10
   <sup>3</sup>至1 &#215; 10
   <sup>4</sup>，同组间T细胞扩增指数逐渐增加(p均 &lt; 0.01)，1 &#215; 10
   <sup>4</sup>与5 &#215; 10
   <sup>4</sup>之间T细胞扩增指数的增加无统计学意义(p &gt; 0.05)。② T细胞分泌细胞因子：当刺激细胞数为5 &#215; 10
   <sup>4</sup>时，对照组与1组、2组IL-12含量的比较均无显著性差异(p &gt; 0.05)；3组、4组、5组明显高于对照组，亦明显高于1组(p均 &lt; 0.01)。对照组与1组、2组IFN-γ含量的比较均无显著性差异(p &gt; 0.05)；3组、4组、5组明显高于对照组，亦明显高于1组(p均 &lt; 0.01)。2) 杀瘤活性结果显示：实验各组杀伤HL-60细胞活性均较对照组显著增强(p均 &lt; 0.01)；当MDP浓度由10
   <sup>2</sup> ug/l递增至10
   <sup>4</sup> ug/l，2组、3组、4组、5组组间比较，杀伤活性逐渐增加(p均 &lt; 0.01)，以5组杀伤HL-60细胞活性最强。结论：① 当MDP诱导后的DC数量 ≥ 1 &#215; 10
   <sup>3</sup>时，即能促进T细胞的增殖，且有MDP浓度依赖性。② 经MDP诱导后的DC具有促进T细胞分泌的作用，与细胞因子联合作用更强。③ MDP能从儿童急性白血病骨髓中诱导出有较强的抗原刺激能力的DC，且有MDP浓度依赖性。
    Objective: To investigate the effect of Muramyl Dipeptide (MDP) on the function of dendritic cells (DC) derived from bone marrow in children with acute leukemia. Methods: The mononuclear cells were isolated from bone marrow in children with acute leukemia by the method of Ficoll-Hypaque and cultured with cytokines in the control group. The test groups contained five subgroups: used MDP (10
   <sup>2</sup> ug/l) alone (Group 1), cytokines combined with MDP of different concentration, which was put in 3rd day (Group 2, 10 ug/l; Group 3, 10
   <sup>2</sup> ug/l; Group 4, 10
   <sup>3</sup> ug/l; Group 5, 10
   <sup>4</sup> ug/l). The DCs were collected in the 9th day. The DCs of different groups were mixed with allogeneic peripheral blood T cells for 96 hours, the numbers of T cells in different groups were counted and the contents of interleukin (IL)-12, interferon-γ (IFN-γ) were tested by enzyme-linked immunosorbent assay (ELISA). The DCs of different groups and T cells (cultured with rhIL-2 + 10%FCS of RPMI1640 for 6 days) and HL-60 cells were cultured for 12 hours, cytotoxicity assay were measured by LDH release. Results: 1) Mixed lymphocyte reaction ① The stimulation index of T cell: When the number of stimulation cells was fixed, the proliferation of allogeneic lymphocytes could be strongly stimulated. There was no difference among the control group, group 1 and group 2; but the group3, group 4 and group 5 were higher than the control group and group 1 (p &lt; 0.01). With the increasing of the number of stimulation cells from 1 &#215; 10
   <sup>3</sup> to 1 &#215; 10
   <sup>4</sup>, the stimulation index of T cells was rising, and the group3, group 4 and group 5 were significantly higher than the control group and group 1, but there was no difference among the control group, group 1 and group 2. ② The contains of IL-12, IFN-γ: When the number of stimulation cells was 5 &#215; 10
   <sup>4</sup>, there was no difference among the contains of IL-12 of the control group, group 1 and group 2; the group 3, group 4 and group 5 were higher than the control group and group 1 (p &lt; 0.01). There was no difference among the contains of IFN-γ of the control group, group 1 and group 2; the group 3, group 4 and group 5 were higher than the control group and group 1 (p &lt; 0.01). 2) Cytotoxicity assay showed that killing activity on HL-60 cells of T cells in test groups was higher than that of the control group, and in test groups, with the increasing of the concentration of MDP from 10
   <sup>2</sup> ug/l to 10
   <sup>4</sup> ug/l, the killing activity on HL-60 cells was dramatically enhanced (p &lt; 0.01), among which the killing activity of the group 5 was the strongest. Conclusion: ① The proliferation of T cells could be promoted when the number of DCs induced with MDP is ≥ 1 &#215; 10
   <sup>3</sup>, and its function has MDP concentration dependence. ② The DCs induced with MDP could promote T cells secretion, and has no difference between cytokines, but the combined application effect is more obvious. ③ MDP could induce functional DCs to be generated from bone marrow in children with acute leukemia, and its function has MDP concentration dependence. 
  
 
</p></abstract><kwd-group><kwd>胞壁酰二肽，树突状细胞，白血病，免疫功能，增殖, Muramyl Dipeptide</kwd><kwd> Dendritic Cells</kwd><kwd> Leukemia</kwd><kwd> Immunifaction</kwd><kwd> Proliferation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>胞壁酰二肽对儿童急性白血病骨髓树突状细胞功能的影响<sup> </sup></title><p>李晓玲<sup>1*</sup>，朱政<sup>2*</sup>，孙立荣<sup>3#</sup></p><p><sup>1</sup>临沂市人民医院儿内三科，山东 临沂</p><p><sup>2</sup>上海中医药大学康复医学院，上海</p><p><sup>3</sup>青岛大学医学院附属医院小儿血液科，山东 青岛</p><disp-formula id="hanspub.26241-formula13"><graphic xlink:href="//html.hanspub.org/file/2-1570625x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2018年6月29日；录用日期：2018年7月26日；发布日期：2018年8月2日</p><disp-formula id="hanspub.26241-formula14"><graphic xlink:href="//html.hanspub.org/file/2-1570625x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探讨胞壁酰二肽(MDP)对儿童急性白血病骨髓树突状细胞(DC)功能的影响。方法：应用Ficoll-Hypaque法分离急性白血病患儿骨髓单个核细胞，对照组：用细胞因子诱导培养DC；实验组实验组分为5个亚组，1组：与对照组等量的MNC+ MDP (10 ug/l)，2~5组分别对应为：与对照组等量的MNC + 与对照组等量的细胞因子 + 不同浓度的MDP (10<sup>2</sup> ug/l，10<sup>2</sup> ug/l，10<sup>3</sup> ug/l，10<sup>4</sup> ug/l)；分别诱导培养DC，第9天收获各组DC，与同种异体外周血T淋巴细胞混合反应96 h，观察淋巴细胞的增殖情况，ELISA方法检测上清液中IL-12、IFN-γ的含量；经HL-60抗原致敏后的DC与T淋巴细胞混合培养6 d后，加入HL-60细胞共同孵育12 h，LDH释放改良法检测各组细胞毒T淋巴细胞(CTL)的杀伤活性。结果：1) 混合淋巴细胞反应显示：① T细胞扩增指数：固定刺激细胞数，不同组比较，对照组与1组、2组比较均无显著性差异(p均 &gt; 0.05)；3组、4组、5组T细胞扩增指数明显高于对照组，亦明显高于1组(p均 &lt; 0.01)。当刺激细胞数量为1 &#215; 10<sup>3</sup>至1 &#215; 10<sup>4</sup>，同组间T细胞扩增指数逐渐增加(p均 &lt; 0.01)，1 &#215; 10<sup>4</sup>与5 &#215; 10<sup>4</sup>之间T细胞扩增指数的增加无统计学意义(p &gt; 0.05)。② T细胞分泌细胞因子：当刺激细胞数为5 &#215; 10<sup>4</sup>时，对照组与1组、2组IL-12含量的比较均无显著性差异(p &gt; 0.05)；3组、4组、5组明显高于对照组，亦明显高于1组(p均 &lt; 0.01)。对照组与1组、2组IFN-γ含量的比较均无显著性差异(p &gt; 0.05)；3组、4组、5组明显高于对照组，亦明显高于1组(p均 &lt; 0.01)。2) 杀瘤活性结果显示：实验各组杀伤HL-60细胞活性均较对照组显著增强(p均 &lt; 0.01)；当MDP浓度由10<sup>2</sup> ug/l递增至10<sup>4</sup> ug/l，2组、3组、4组、5组组间比较，杀伤活性逐渐增加(p均 &lt; 0.01)，以5组杀伤HL-60细胞活性最强。结论：① 当MDP诱导后的DC数量 ≥ 1 &#215; 10<sup>3</sup>时，即能促进T细胞的增殖，且有MDP浓度依赖性。② 经MDP诱导后的DC具有促进T细胞分泌的作用，与细胞因子联合作用更强。③ MDP能从儿童急性白血病骨髓中诱导出有较强的抗原刺激能力的DC，且有MDP浓度依赖性。</p><p>关键词 :胞壁酰二肽，树突状细胞，白血病，免疫功能，增殖</p><disp-formula id="hanspub.26241-formula15"><graphic xlink:href="//html.hanspub.org/file/2-1570625x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2018 by authors and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1570625x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-1570625x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>免疫细胞治疗是继化疗、骨髓移植(bone marrow transplantation, BMT)后治疗白血病的一种新方法，在治疗白血病及清除微小残留病(minimal residual disease, MRD)中被寄予很大希望。树突状细胞(dendritic cell, DC)是目前所知抗原提呈能力最强的抗原提呈细胞(antigen presenting cells, APC)，在肿瘤细胞和 T淋巴细胞的相互作用中起桥梁和枢纽作用。大量的动物实验证明，DC可以诱导机体特异性免疫反应的发生，使机体得以抵御肿瘤的入侵或消灭机体现存的肿瘤 [<xref ref-type="bibr" rid="hanspub.26241-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.26241-ref2">2</xref>]。胞壁酰二肽(N-乙酰胞壁酰-L-Ala-D-isoGln，即壁氨酰-L-丙氨酰-D-谷氨酰胺，Muramyl Dipeptide，简称MDP)是具有免疫增强活性的分枝杆菌细胞壁的最小有效成分 [<xref ref-type="bibr" rid="hanspub.26241-ref3">3</xref>]，对肿瘤及病原微生物具有免疫刺激及免疫治疗作用。本文就MDP在体外对儿童急性白血病骨髓来源DC的扩增和相关免疫功能进行研究。</p></sec><sec id="s4"><title>2. 材料和方法</title><sec id="s4_1"><title>2.1. 材料</title><sec id="s4_1_1"><title>2.1.1. 骨髓来源</title><p>急性淋巴细胞性白血病患儿诊断和疗效均按血液病诊断及疗效标准，其中诊断标准：临床出现典型的症状体征(贫血、出血、感染、脏器浸润症状)，外周血有/无幼稚细胞，骨髓原始加幼稚淋巴细胞 ≥ 30%；完全缓解的标准：1) 临床无贫血、出血、感染及白血病细胞浸润表现；2) 血象：血红蛋白 &gt; 90 g/L，白细胞正常或减低，分类无幼稚细胞，血小板 &gt; 100 &#215; 10<sup>9</sup>/L；3) 骨髓象：原始加幼稚淋巴细胞 &lt; 5%，红细胞系统及巨核细胞系统正常。所有患儿均顺利完成化疗并完全缓解达6个月以上，无复发及其它并发症。住院当日无菌采集骨髓5 ml，肝素抗凝(20 U/ml)。</p></sec><sec id="s4_1_2"><title>2.1.2. 细胞来源</title><p>HL-60细胞株购自中国科学院上海生命科学研究院。</p></sec><sec id="s4_1_3"><title>2.1.3. 主要试剂</title><p>胞壁酰二肽(Sigma公司)；重组人粒细胞–巨噬细胞集落刺激因子(recombinant human granulocyte-macrophage colony-stimulating factor, rhGM-CSF)、重组人肿瘤坏死因子-α (recombinant human tumor necrosis factor-α, rhTNF-α)、重组人白细胞介素(Recombinant human interleukin, rhIL)-2, 4 (Peprotech Asia公司)；人白介素-12定量酶联检测试剂盒(IL-12)、人干扰素-γ定量酶联检测试剂盒(IFN-γ) (Jingmei Biotech公司)。</p></sec></sec><sec id="s4_2"><title>2.2. 方法</title><sec id="s4_2_1"><title>2.2.1. HL-60细胞株的培养及其全细胞抗原的制备</title><p>以含10% FCS的IMDM培养液于37℃、5% CO<sub>2</sub>、饱和湿度培养箱中孵育，每2~3天半量换液，传代培养HL-60细胞。收集对数生长期HL-60细胞，PBS洗涤(约1.0 &#215; 10<sup>6</sup> cells/ml)，放入液氮中速冻，后迅速放入37℃水浴中慢融，反复4次，所得细胞裂解液离心后，上清液稀释至1 ml，0.22 um微孔滤膜过滤，−20℃保存备用。</p></sec><sec id="s4_2_2"><title>2.2.2. 骨髓单个核细胞(Mononuclear Cells, MNC)的分离</title><p>无菌采集抗凝骨髓5 ml，Ficoll-paque法分离MNC，调整细胞浓度为1 &#215; 10<sup>6</sup>/ml，接种于24孔培养板，于37℃，5% CO<sub>2</sub>孵箱中贴壁3~4 h。</p></sec><sec id="s4_2_3"><title>2.2.3. 骨髓血树突状细胞(DC)的诱导</title><p>将上述细胞分组：对照组：MNC + rhGM-CSF (100 ng/ml) + IL-4 (100 ng/ml) + rhTNF-α (20 ng/ml)；实验组分为5个亚组，1组：与对照组等量的MNC + MDP (10 ug/l)，2~5组分别对应为：与对照组等量的MNC+与对照组等量的细胞因子+不同浓度的MDP (10<sup>2</sup> ug/l，10<sup>2</sup> ug/l，10<sup>3</sup> ug/l，10<sup>4</sup> ug/l)；各组细胞均在37℃，5% CO<sub>2</sub>孵箱中培养，隔天半量换液及全量补充细胞因子与MDP。</p><p>培养过程中，倒置显微镜下每日观察细胞生长情况及形态变化。培养第9天，收取各组细胞进行实验。</p></sec><sec id="s4_2_4"><title>2.2.4. 混合淋巴细胞反应(Mixed Lymphocyte Reaction, MLR)</title><p>无菌采集抗凝外周血5 ml，Ficoll-paque法分离获得MNC，37℃、5% CO<sub>2</sub>孵箱中贴壁3~4 h后取收集悬浮细胞，调整细胞浓度为1 &#215; 10<sup>6</sup>/ml，加入rhIL-2 (20 ng/ml)，37℃，5% CO<sub>2</sub>孵箱中培养，隔天半量换液及全量补充细胞因子，第7天收获全部悬浮细胞，作为效应细胞。取培养第9天的对照组及实验组的DC作为刺激细胞。</p><p>1) 淋巴细胞增殖能力测定</p><p>刺激细胞分别以空白/孔、1 &#215; 10<sup>3</sup>/孔、5 &#215; 10<sup>3</sup>/孔、1 &#215; 10<sup>4</sup>/孔、5 &#215; 10<sup>4</sup>/孔接种于96孔培养板，分别加入1 &#215; 10<sup>5</sup>效应细胞，于37℃、5% CO<sub>2</sub>孵箱中进行混合淋巴细胞培养96 h后，加入MTT (20 ul/孔)，继续孵育4 h，400&#215;g，10 min终止培养，吸走上清，加入DMSO (150 ul/孔)，酶标仪上于波长490 nm处检测A490值。</p><p>刺 激 指 数 ( SI ) = 加 刺 激 细 胞 孔 A49 0 值 / 不 加 刺 激 细 胞 孔 A49 0 值</p><p>2) 细胞因子IL-12和IFN-γ的测定</p><p>MLR 96 h后，在刺激细胞为5 &#215; 10<sup>4</sup>/孔条件下，ELISA法测定上清中IL-12和IFN-γ含量。</p></sec><sec id="s4_2_5"><title>2.2.5. 抗白血病细胞(HL-60)细胞毒效应</title><p>1) DC致敏</p><p>同上述骨髓MNC的分离和DC的培养方法一致，但分别于第4天、第7天的DC培养体系中两次加入HL-60全细胞抗原肽(DC:HL-60 = 10:1)，致敏DC。将10<sup>6</sup>/ml淋巴细胞与10<sup>5</sup>/ml致敏后DCHL-60细胞混合培养于96孔板中，加入rhIL-2 (20 ng/ml)共培养6 d，获得细胞毒T淋巴细胞(cytotoxic T lymphocyte, CTL)，作为效应细胞。调整HL-60细胞浓度为1.0 &#215; 10<sup>5</sup>/ml作为靶细胞(效:靶 = 10:1)，37℃、5% CO<sub>2</sub>孵箱中12 h后，离心收集上清液，采用LDH释放试剂盒检测LDH含量，酶标仪上于波长490 nm处测定吸光度(A)。</p><p>杀伤活性 = (实验组A − 靶细胞自然释放组A − 效应细胞自然释放组A)/(靶细胞最大释放组A − 靶细胞自然释放组A) &#215; 100% [<xref ref-type="bibr" rid="hanspub.26241-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.26241-ref5">5</xref>]</p></sec><sec id="s4_2_6"><title>2.2.6. 统计学处理</title><p>数据用均数 &#177; 标准差( x &#175; &#177; S)表示，随机区组设计资料采用方差分析，均数间的相互比较采用t检验。</p></sec></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 对T细胞扩增的影响</title><p>当刺激细胞数一定时，不同组比较，对照组与1组、2组比较均无显著性差异(p均 &gt; 0.05)；3组、4组、5组T细胞扩增指数明显高于对照组，亦明显高于1组(p均 &lt; 0.01)。当刺激细胞数量为1 &#215; 10<sup>3</sup>至1 &#215; 10<sup>4</sup>，同组间T细胞扩增指数逐渐增加(p均 &lt; 0.01)，1 &#215; 10<sup>4</sup>与5 &#215; 10<sup>4</sup>之间T细胞扩增指数的增加无统计学意义(p &gt; 0.05)。见表1。</p></sec><sec id="s5_2"><title>3.2. 对T细胞分泌细胞因子的影响</title><p>当刺激细胞数为5 &#215; 10<sup>4</sup>时，对照组与1组IL-12含量分别为(69.78 &#177; 7.40) pg/ml，(67.94 &#177; 9.69) pg/ml，两组间比较无显著性差异(t = 0.43, p &gt; 0.05)；2组为(78.18 &#177; 10.72) pg/ml，与对照组及1组比较均无显著性差异(t = 1.82、2.00, p &gt; 0.05)；3组、4组、5组明显高于对照组(t = 8.31、10.63、12.16，p均 &lt; 0.01)，亦明显高于1组(t = 8.25、10.61、11.90，p均 &lt; 0.01)。</p><p>对照组与1组IFN-γ含量分别为(75.93 &#177; 9.25) pg/ml，(73.17 &#177; 8.13) pg/ml，两组间比较无显著性差异(t = 0.63, p &gt; 0.05)；2组为(81.92 &#177; 10.01) pg/ml，与对照组及1组比较均无显著性差异(t = 1.24、1.92, p &gt; 0.05)；3组、4组、5组明显高于对照组(t = 9.21、12.62、15.38，p均 &lt; 0.01)，亦明显高于1组(t = 9.59、12.77、15.66，p均 &lt; 0.01)。见图1。</p></sec><sec id="s5_3"><title>3.3. DC诱导的特异性抗白血病细胞毒效应</title><p>各组杀伤活性：对照组(47.54 &#177; 3.62)%；1组(58.43 &#177; 2.91)%；2组(73.58 &#177; 3.88)%；3组(82.12 &#177; 3.21)%；4组(90.53 &#177; 3.85)%；5组(98.90 &#177; 3.72)%。实验各组杀伤HL-60细胞活性均较对照组组显著增强(t = 5.24、10.97、15.98、18.19、22.69，p均 &lt; 0.01)；当MDP浓度由10<sup>2</sup> ug/l递增至10<sup>4</sup> ug/l，2组、3组、4组、5组组间比较，杀伤活性逐渐增加(2组与其余组比较：t = 3.79、7.34、10.32；3组与4、5组比较：t = 3.75、7.38；4与5组比较：t = 3.50，p均 &lt; 0.01)，以5组杀伤HL-60细胞活性最强。见图2。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of the stimulation index of T cell in different groups ( x &#175; &#177; S</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >Group</th><th align="center" valign="middle"  colspan="4"  >Stimulating cells (&#215;10<sup>3</sup>/well)</th></tr></thead><tr><td align="center" valign="middle" >1 (A)</td><td align="center" valign="middle" >5 (B)</td><td align="center" valign="middle" >10 (C)</td><td align="center" valign="middle" >50 (D)</td></tr><tr><td align="center" valign="middle" >Control</td><td align="center" valign="middle" >1.86 &#177; 0.11</td><td align="center" valign="middle" >2.31 &#177; 0.23</td><td align="center" valign="middle" >2.72 &#177; 0.28<sup>⊿</sup></td><td align="center" valign="middle" >2.92 &#177; 0.30</td></tr><tr><td align="center" valign="middle" >Group 1</td><td align="center" valign="middle" >1.82 &#177; 0.13<sup>●</sup></td><td align="center" valign="middle" >2.29 &#177; 0.21<sup>●</sup></td><td align="center" valign="middle" >2.69 &#177; 0.23<sup>●</sup></td><td align="center" valign="middle" >2.87 &#177; 0.27<sup>●</sup></td></tr><tr><td align="center" valign="middle" >Group 2</td><td align="center" valign="middle" >1.91 &#177; 0.18<sup>★</sup></td><td align="center" valign="middle" >2.44 &#177; 0.19<sup>★</sup></td><td align="center" valign="middle" >2.75 &#177; 0.20<sup>★</sup></td><td align="center" valign="middle" >2.97 &#177; 0.25<sup>★</sup></td></tr><tr><td align="center" valign="middle" >Group 3</td><td align="center" valign="middle" >2.62 &#177; 0.27<sup>◆</sup></td><td align="center" valign="middle" >2.91 &#177; 0.22<sup>◆</sup></td><td align="center" valign="middle" >3.34 &#177; 0.24<sup>◆</sup></td><td align="center" valign="middle" >3.58 &#177; 0.28<sup>◆</sup></td></tr><tr><td align="center" valign="middle" >Group 4</td><td align="center" valign="middle" >2.77 &#177; 0.23<sup>◆</sup></td><td align="center" valign="middle" >3.15 &#177; 0.24<sup>◆</sup></td><td align="center" valign="middle" >3.54 &#177; 0.27<sup>◆</sup></td><td align="center" valign="middle" >3.77 &#177; 0.31<sup>◆</sup></td></tr><tr><td align="center" valign="middle" >Group 5</td><td align="center" valign="middle" >2.91 &#177; 0.19<sup>◆</sup></td><td align="center" valign="middle" >3.49 &#177; 0.27<sup>◆</sup></td><td align="center" valign="middle" >3.93 &#177; 0.25<sup>◆⊿</sup></td><td align="center" valign="middle" >4.18 &#177; 0.29<sup>◆</sup><sup>▼</sup></td></tr></tbody></table></table-wrap><p>表1. 不同组间T细胞扩增指数比较</p><p>F1 = 40.50, F2 = 32.36, p &lt; 0.01; <sup>Δ</sup>P &lt; 0.01, compared among group C, B and A, t = 8.96, 9.94, 12.23; <sup>▼</sup>P &gt; 0.05, compared group D with C, t = 0.16; <sup>★</sup>P &gt; 0.05, compared with the control group, t = 0.67, 0.28, 0.27, 0.36; compared with the group 1, t = 1.15, 0.50, 0.56, 0.77; <sup>●</sup>P &gt; 0.05, compared with the control group, t = 0.66, 0.18, 0.23, 0.35; <sup>◆</sup>P &lt; 0.01, compared with the control group, t<sub>A</sub> = 7.37, 10.10, 13.53, t<sub>B</sub> = 4.44, 6.30, 8.54, t<sub>C</sub> = 4.77, 5.96, 9.12, t<sub>D</sub> = 4.55, 5.57, 8.54; compared with the group 1, t<sub>A</sub> = 8.49, 10.24, 13.39, t<sub>B</sub> = 4.84, 6.74, 8.13, t<sub>C</sub> = 5.53, 6.78, 10.32, t<sub>D</sub> = 5.16, 6.19, 9.35.</p><p>图1. T细胞分泌细胞因子(IL-12、IFN-γ)含量</p><p>图2. LDH法检测细胞杀伤活性</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>MRD是白血病容易复发的主要根源，是治愈白血病的主要障碍。通过相关的技术方法增强白血病细胞的免疫原性，进而诱导机体产生肿瘤特异性的细胞免疫应答消除肿瘤细胞，可望达到治愈白血病的目的。</p><p>CD8<sup>+</sup> CTL是有效的抗肿瘤细胞免疫的核心。但是由于肿瘤细胞抗原表达较弱、共刺激因子缺乏等原因，宿主T细胞不能有效地识别和杀伤肿瘤细胞。因而如何更好地激发机体抗肿瘤免疫成为研究的热点。</p><p>DC是免疫系统中最强的APCs，表面HLA和共刺激因子的表达增强，可释放T细胞刺激因子(主要是IL-12)，T细胞增殖且特异性针对DC递呈的抗原发挥作用。在混合淋巴细胞反应中，DC不仅能原位致敏CD<sub>4</sub><sup>+</sup>T淋巴细胞，而且在体外可有效地诱导同种异体CD<sub>8</sub><sup>+</sup>T淋巴细胞增殖，是DC用于临床治疗恶性肿瘤的基础 [<xref ref-type="bibr" rid="hanspub.26241-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.26241-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.26241-ref8">8</xref>]。</p><p>MDP是人工合成的分枝杆菌细胞壁中具有佐剂活性作用的最小结构单位，可有效提高IL-1、IL-6和GSF等多种细胞因子的分泌水平，对一部分肿瘤已显示出明确的免疫治疗作用 [<xref ref-type="bibr" rid="hanspub.26241-ref9">9</xref>]。目前，极多数学者研究卡介苗激活DCs为主的APCs对肿瘤抗原的递呈能力增强进而激活CTLs针对肿瘤细胞的特异性免疫反应，以及可诱导肿瘤细胞和局部免疫细胞产生IL-1、IL-6、IL-8、IL-2、IL-12、INF-γ等细胞因子，发挥直接抗肿瘤作用、免疫细胞网络调节效应和放大免疫细胞抗肿瘤活性 [<xref ref-type="bibr" rid="hanspub.26241-ref10">10</xref>]。推测MDP也可能具有诱导扩增DC，促进T细胞的增殖、分泌及杀瘤的功能。</p><p>本研究组既往实验证实：从儿童急性白血病骨髓中分离出MNC，分别采用GM-CSF+IL-4+TNF-α、MDP及GM-CSF + IL-4 + TNF-α + MDP诱导，均得到一定数量的典型DCs [<xref ref-type="bibr" rid="hanspub.26241-ref11">11</xref>]。本文中MDP诱导后的DC，在1 &#215; 10<sup>3</sup>即能促进T细胞的增殖和分泌IL-12、IFN-γ，且随着MDP浓度由10<sup>2</sup> ug/l递增至10<sup>4</sup> ug/l，作用进一步增强；并且CTL细胞的杀瘤活性亦随着MDP浓度的增加逐步增强。生理情况下IL-12主要来源于DC，除有明显的抗肿瘤作用外，尚能促进T淋巴细胞增殖，诱导产生IFN-γ。IFN-γ促进DC迅速增殖，并分化为成熟的效应性CTL，发挥免疫抗肿瘤作用 [<xref ref-type="bibr" rid="hanspub.26241-ref12">12</xref>]。以上作用在细胞因子联合MDP应用后效果更为明显。说明当MDP诱导后的DC数量 ≥ 1 &#215; 10<sup>3</sup>时，即能促进T细胞的增殖，且有MDP浓度依赖性。而且，经MDP诱导后的DC具有促进T细胞分泌的作用，与细胞因子联合作用更强。另外，MDP能从儿童急性白血病骨髓中诱导出有较强的抗原刺激能力的DC，亦具有MDP浓度依赖性。由于MDP具有免疫增强活性和高效低毒特点，对肿瘤进行免疫治疗，将可能具有较大的临床潜在应用价值。</p></sec><sec id="s7"><title>文章引用</title><p>李晓玲,朱 政,孙立荣. 胞壁酰二肽对儿童急性白血病骨髓树突状细胞功能的影响 Effect of Muramyl Dipeptide on the Immunifaction of Dendritic Cells Derived from Bone Marrow in Children with Acute Leukemia[J]. 临床医学进展, 2018, 08(06): 507-513. https://doi.org/10.12677/ACM.2018.86085</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.26241-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Fields, R.C., Shimizu, K., Mule, J.J., et al. (1998) Murine Dendritic Cells Pulsed with Whole Tumor Lysates Mediate Potent Anti-Tumor Immune Responses in Vitro and in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 95, 9482-9487. &lt;br&gt;https://doi.org/10.1073/pnas.95.16.9482</mixed-citation></ref><ref id="hanspub.26241-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Saha, A., Chatterjee, S.K., Foon, K.A., et al. (2003) Murine Dendritic Cells Pulsed with an Anti-Idiotype Antibody Induce Antigen-Specific Protective Antitumor Immunity. Cancer Research, 63, 2844-2854.</mixed-citation></ref><ref id="hanspub.26241-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Uehori, J., Fukase, K., Akazawa, T., et al. (2005) Dendritic Cell Maturation Induced by Muramyl Dipeptide (MDP) Derivatives: Monoacylated MDP Confers TLR2/TLR4 Activation. The Journal of Immunology, 174, 7096-7103.  
&lt;br&gt;https://doi.org/10.4049/jimmunol.174.11.7096</mixed-citation></ref><ref id="hanspub.26241-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Weidnann, E., Brieger, J., Jahn, B., et al. (1995) Lactate Dehydrogenase Release Assay: A Reliable Nonradioactive Technique for Analysis of Cytotoxic Lymphocyte-Mediate Lytic Activity against Blasts from Acute Myelocytic Leukemia. Annals of Hematology, 70, 153-158. &lt;br&gt;https://doi.org/10.1007/BF01682036</mixed-citation></ref><ref id="hanspub.26241-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Pirious, L., Chilmonczyk, S., Genetetet, N., et al. (2000) Design of a Flow Cytometric Assay for the Determination of Natural Killer and Cytotoxic T-Lymphocyte Activity in Human and in Different Animal Species. Cytometry, 41, 289-297. &lt;br&gt;https://doi.org/10.1002/1097-0320(20001201)41:4&lt;289::AID-CYTO7&gt;3.0.CO;2-5</mixed-citation></ref><ref id="hanspub.26241-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Banchereau, J., Briere, F., Caux, C., et al. (2000) Immunobiology of Dendritic Cells. Annual Review of Immunology, 18, 767-811. &lt;br&gt;https://doi.org/10.1146/annurev.immunol.18.1.767</mixed-citation></ref><ref id="hanspub.26241-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Nagaraj, S., Ziske, C. and Schmidt-Wolf, I.G. (2004) Human Cytokine-Induced Killer Cells Have Enhanced in Vitro Cytolytic Activity via Non-Viral Interleukin-2 Gene Transfer. Genetic Vaccines and Therapy, 2, 12.  
&lt;br&gt;https://doi.org/10.1186/1479-0556-2-12</mixed-citation></ref><ref id="hanspub.26241-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Vulink, A., Radford, K.J., Melief, C., et al. (2008) Dendritic Cells in Cancer Immunotherapy. Advances in Cancer Research, 99, 363-407. &lt;br&gt;https://doi.org/10.1016/S0065-230X(07)99006-5</mixed-citation></ref><ref id="hanspub.26241-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Muhlradt, P.F. and Frisch, M. (2004) Purification and Partial Characterization of a Mycoplasma Fermentans-Derived Substance That Activates Macrophages to Release Nitric Oxide, Tumor Necrosis Factor, and Interleukin-6. Infection and Immunity, 62, 3801-3808.</mixed-citation></ref><ref id="hanspub.26241-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Cheadle, E.J., Selby, P.J. and Jackon, A.M. (2003) Mycobacterium bovis Bacillus Calmete–Guerin-Infected Dendritic Cells Potently Activate Autologous T Cells via a B7 and Interleukin-12-Dependent Mechanism. Immunology, 108, 79-88. &lt;br&gt;https://doi.org/10.1046/j.1365-2567.2003.01543.x</mixed-citation></ref><ref id="hanspub.26241-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">李晓玲, 孙立荣. 胞壁酰二肽对儿童急性白血病骨髓树突状细胞体外扩增的影响[J]. 中国实验血液学杂志, 2010, 18(4): 963-966.</mixed-citation></ref><ref id="hanspub.26241-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">曲春枫, 顾培娣, 鞠吉雨, 等. IL-12 基因转染的人树突状细胞加强细胞免疫反应的体外研究[J]. 中国免疫学杂志, 2000(12): 638-640, 647.</mixed-citation></ref></ref-list></back></article>